Association Between Symptom Improvement and Change of Body Mass Index, Lipid Profile, and Leptin, Ghrelin, and Cholecystokinin Levels During 6-Week Olanzapine Treatment in Patients With First-Episode Psychosis
- 1 October 2010
- journal article
- letter
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 30 (5) , 636-638
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Systemic administration of ghrelin increases extracellular dopamine in the shell but not the core subdivision of the nucleus accumbensNeurochemistry International, 2009
- Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysisSchizophrenia Research, 2007
- Illuminating the molecular basis for some antipsychotic drug-induced metabolic burdenProceedings of the National Academy of Sciences, 2007
- PRECLINICAL STUDY: Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbensAddiction Biology, 2006
- Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetiteJournal of Clinical Investigation, 2006
- PRECLINICAL STUDY: Ghrelin stimulates locomotor activity and accumbal dopamine‐overflow via central cholinergic systems in mice: implications for its involvement in brain rewardAddiction Biology, 2006
- Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidolThe British Journal of Psychiatry, 2005
- Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychoticJournal of Psychopharmacology, 2005
- Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential AssociationJournal of Clinical Psychopharmacology, 2002
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987